List of Trilipix drug patents

Trilipix is owned by Abbvie.

Trilipix contains Choline Fenofibrate.

Trilipix has a total of 1 drug patent out of which 0 drug patents have expired.

Trilipix was authorised for market use on 15 December, 2008.

Trilipix is available in capsule, delayed release;oral dosage forms.

The generics of Trilipix are possible to be released after 07 January, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7259186 ABBVIE Salts of fenofibric acid and pharmaceutical formulations thereof
Jan, 2025

(1 year, 10 months from now)

Drugs and Companies using CHOLINE FENOFIBRATE ingredient

Market Authorisation Date: 15 December, 2008

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of TRILIPIX before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in